FibroGen
FGEN
Market cap $26.7M

0.2639 USD

-0.0446

14.46%

At close Jun 13, 4:00 PM EDT

After hours

0.2699

+0.0060

2.27%

1 day

-14.46%

5 days

-13.81%

1 month

-11.83%

3 months

-38.21%

6 months

-20.73%

Year to date

-50.14%

1 year

-77.25%

5 years

-99.33%

10 years

-98.60%

About: FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Employees: 225

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

320% more call options, than puts

Call options by funds: $193K | Put options by funds: $46K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

3.3% less ownership

Funds ownership: 35.97% [Q4 2024] → 32.67% (-3.3%) [Q1 2025]

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

19% less funds holding

Funds holding: 69 [Q4 2024] → 56 (-13) [Q1 2025]

47% less capital invested

Capital invested by funds: $19.2M [Q4 2024] → $10.2M (-$8.97M) [Q1 2025]

72% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 18

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$10

3,689%

upside

Avg. target

$10

3,689%

upside

High target

$10

3,689%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Joseph Pantginis

3,689%upside

$10

Buy

Reiterated

13 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about FGEN published over the past 30 days

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Friday.

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

FibroGen Announces 1-for-25 Reverse Stock Split

SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen's common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company's existing trading symbol “FGEN,” with the new CUSIP number 31572Q881.

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - Chief Executive Officer David DeLucia - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Matthew Keller - H.C. Wainwright Operator Good day and thank you for standing by.

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

Zacks Investment Research

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.33 per share a year ago.

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments.

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence R&D Duchenne Muscular Dystrophy. The therapies under development are focused on novel approaches to treat/improve Duchenne Muscular Dystrophy. Duchenne Muscular Dystrophy Emerging Drugs

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN ) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - CEO David DeLucia - CFO Conference Call Participants Andy Sieh - William Blair Matthew Keller - H.C. Wainwright Operator Hello everyone, and welcome to the FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call.

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™